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Background: Differences in expression of drug transporters in human kidney contribute to changes in
pharmacokinetics and toxicokinetics of a variety of drug compounds. The basal expression levels of genes involved
in drug transport processes in the kidney introduces differences in bioavailability, distribution, and clearance of
drugs, possibly influencing drug efficacy and adverse reactions. Sex differences in gene expression of transporters are
a key cause of differences in sex-dependent pharmacokinetics, which may characterize many drugs and contribute to
individual differences in drug efficacy and toxicity. Therefore, evaluating the expression of drug transporters in normal
human kidneys is important to better understand differences in drug bioavailability, distribution, and clearance of drugs
in humans. Other factors such as age and ethnicity may also contribute to individual differences in gene expression of
drug transporters in the human kidney.
Methods: Quantitative real-time PCR (QRT-PCR) was performed to determine the gene expression of 30 drug transporters
in 95 age-matched normal human kidney tissues. Multiple Student’s t-tests (Sidak-Bonferroni correction) and two-way
ANOVA (Bonferroni correction) analyses were used to determine statistically significant differences.
Results: In the 30 transporter genes examined, sex, ethnicity, and age differences in gene expression were exhibited in
normal human kidney tissue. These changes in expression were not found to be differentially significant. However,
sex-age and sex-ethnicity interactions were found to be statistically significant. For sex-age interactions, SCL22A12 was
found to be significantly higher expressed in females <50 years compared to males <50 years. Expression levels of
SLC22A2, SLC22A12, SLC6A16, and ABCB6 were significantly higher in females <50 years compared to females ≥50 years.
In sex-ethnicity interactions, expression levels of ATP7B and KCNJ8 were found to be significantly higher in African
American females compared to European American females. Also, the expression of SLC31A2 was significantly higher
in European American males compared to European American females.
Conclusions: Sex, age, and ethnic differences impacted the expression of drug transporters in normal human kidneys,
which suggests that the analysis of gene expression of drug transporters will aid in improving the usage/dosage of drug
therapies influencing personalized medicine and susceptibility to adverse drug reactions.
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One of the main pharmacokinetic organs, the kidney, is
responsible for maintaining fundamental physiological
processes in the human body, such as the regulation of
electrolytes, fluid balance, blood pressure, the production
of various hormones, the reabsorption of key nutrients
and other small molecules, and the metabolism, excretion,
and transport of small molecules, drugs, and xenobiotics
[1-3]. In the kidney, transporters, which are members of
the ATP-binding cassette (ABC) and solute carrier
(SLC) superfamilies, are responsible for recognizing
and transporting metabolites, hormones, and organic
substrates, such as pharmaceutical agents [4]. Drug
transporters, in particular, ABCs (efflux transporters)
and SLCs (uptake transporters), have been identified
as accepted elements in the pharmacokinetics and
toxicokinetics of a variety of drugs and have significant
influence on a drug’s disposition, efficacy, and toxicity
[5-7]. The variability of drug responses among individuals
occurs because of complex and multifactorial contributions
from genetic, environmental, disease/health, and drug-
drug interactions [8]. These factors alter drug absorption,
metabolism, and pharmacokinetics in humans and lead to
inter-individual variability of drug efficacy, safety, and
adverse drug reactions [6,8]. Therefore, understanding the
underlying factors that affect the pharmacokinetics and
pharmacodynamics of pharmaceutical agents in a diverse
population is essential in improving therapeutic efficiency
while diminishing adverse events. Many factors influence
the concentration of a drug in circulation or at the site of
action and determine the resulting outcomes; one of these
factors is the sex of the individual [9-11].
Sex differences in drug efficacy and drug safety have
been widely studied in many epidemiology studies as well
in clinical investigations [1,10,12]. Based on these studies,
sex differences in the expression of drug metabolizing
enzymes and transporters (DMETs) are thought to be one
of the most important determinants accounting for
individual differences in clinical pharmacology, pharmaco-
kinetics, and toxicokinetics leading to differences in drug
efficacy and safety [1,7,12,13]. However, the majority of
these studies focused on DMET processes occurring in
the liver, another key pharmacokinetic organ, instead
of the kidney. Therefore, the elucidation of sexually
differentiated regulation of DMETs in healthy/normal
human kidneys and understanding of its potential impact
on adverse drug reactions is not fully understood.
Two other factors that influence pharmacokinetics
and pharmacodynamics of drug transporters are age and
ethnicity. In aging rats, the kidney is more susceptible to
acute injury resulting in ischemic injury or drug-induced
toxicity. Specific drugs have also been shown to require
age-specific dosing [14-17]. Thus, understanding the rela-
tive influence of age on the renal expression of DMETsthat influence the drug clearance and bioavailability is
critical. Ethnicity is also thought to be a factor that may
contribute to observed differences in both pharmacokinetics
and pharmacodynamics of drugs, which can result in
variability in drug therapy responses. Several studies
have indicated that ethnic differences in DMETs that
contribute to differences in drug response may be a
consequence of diet, medical practices, or genetic differ-
ences [18-20]. Also, studies have shown that certain
genetic differences in drug transporters that are asso-
ciated with different ethnic groups lead to reduced
function, whereas subgroups of the same ethnic group
exhibited similarities in their genetic profiles [20].
However, differences in mRNA expression of drug
transporters have not been extensively studied among
different ethnic groups.
This study was designed to evaluate the inter-individual
variability of renal drug transporters in normal human
kidney tissue. Here, we investigated the mRNA expression
of drug transporters, which were previously identified in a
hepatic study [7], to determine whether or not these
transporters were also expressed in the human kidney.
The selected transporters were mainly comprised of
the two main transporter categories: ABC and SLC
families. Although sex and age differences have been
previously reported in the kidney, most of the published
data are from rat and mouse tissue or human cell lines, not
normal human kidney tissue, which is a more appropriate
model for characterizing sex, race, and age differences in
humans [1,4,17,21]. This study was also motivated by the
observation that data obtained from rats, the most
commonly utilized model in preclinical drug discovery
pharmacokinetics studies, exhibit numerous examples
of discrepancies when compared to data obtained
from humans [4,21]. Our results demonstrate that all
but three of the drug transporters previously identified in
liver are also expressed in the kidney. Further evaluation
also showed that several of these transporters exhibited
not only sex but age and/or ethnic differences in expression.
Methods
Human kidney tissue
Human kidney samples were purchased from the US
Cooperative Human Tissue Networks (CHTN). Information
about the tissue samples regarding ethnicity, sex, age, and
diagnosis was provided. Only normal tissues confirmed by
pathological analysis were utilized. Kidney tissues from 34
females and 61 male age-matched individuals were included
in this study. Age and ethnicity information of the tissue
sample are provided in Table 1. This project was reviewed
by the National Center for Toxicological Research
(NCTR) and Food and Drug Administration (FDA)
Research Involving Human Subject Committee (RIHSC)
and received an exempt status.
Table 1 Subgrouping of 61 male and 34 female normal
kidney tissues
Sex Number Ethnicity Number Age Number
Male 61 <50 2
African American 11 ≥50 9
<50 10
European American 48 ≥50 38
<50 2
Others 2 ≥50 0
Female 34 <50 2
African American 11 ≥50 9
<50 4
European American 21 ≥50 17
<50 1
Others 2 ≥50 1
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Frozen human kidney tissues were ground with a chilled
mortar and pestle for quality RNA isolation. Total RNA
was prepared from the samples using RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s protocol. cDNA was synthesized (reverse transcribed
polymerase chain reaction (RT-PCR)) from 0.4 μg of high
quality RNA (RIN > 8) using the Advantage RT-for-PCR
Kit according to the manufacturer’s protocol (Clontech
Laboratories Inc., Mountain View, CA, USA). The cDNA
concentration was normalized to 20 ng/μl. Fifty nanograms
of cDNA was used per sample reaction.
Quantitative real time- polymerase chain reaction
(QRT-PCR)
For QRT-PCR, SYBR master mix solution was obtained
from Applied Biosystems (Carlsbad, CA, USA) and primers
for GAPDH, ABCA5, ABCB1, ABCB6, ACCN4, ATP2B2,
ATP7B, KCNJ8, KCNK5, MRP1, MXR, MRP5, OST-Beta,
SLC10A1, SLC16A11, SLC22A12, SLC22A2, SLC22A9,
SLC25A13, SLC30A1, SLC31A1, SLC31A2, SLC35F5,
SLC4A1AP, SLC43A1, SLC5A6, SLC5A10, SLC6A16,
SLC9A1, SLCO1B1, and TRPC4AP were obtained from
Sigma-Aldrich (St. Louis, MO, USA). All samples were
assayed in triplicate using a Biorad CFX96 C1000 system
(Biorad, Hercules, CA, USA). ΔΔCT calculations were
used to determine fold change. GAPDH functioned as the
reference gene. QRT-PCR was performed using the
primers listed in Table 2. Expression change ratios greater
than 1.5 were considered differentially expressed.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism software version 6.0 (San Diego, CA, USA). The
non-parametric Mann–Whitney was used to compare
GAPDH expression in the normal human kidney tissuebased on sex, age, or ethnicity. And non-parametric
Kruskal-Wallis was used to compare GAPDH expression
in the normal human kidney tissue based on sex-age and
sex-ethnicity interactions. Multiple Student’s t-test was
performed with the Sidak-Bonferroni correction method
(alpha = 5%) to determine statistically significant differences
in each group; sex, age, or ethnicity. Using multiple
Student’s t-test with Sidak-Bonferroni correction, p < 0.05
was not considered significant. Analysis was significant
when p < 0.0017. Two-way ANOVA with Bonferroni
correction was used to determine statistically significant
differences based on group interaction: sex and age or sex
and ethnicity. Using two-way ANOVA with Bonferroni
correction, p < 0.05 was determined to be significant. For
power analysis, GraphPad Statmate 2 software (San Diego,
CA, USA) was used to determine if the study was suitably
powered to detect statistical difference.
Results
The drug transporter genes selected for this study were
detected in a previous Illumina Human Whole-Genome
BeadChips (Human-6-v1; Illumina, San Diego, CA, USA)
microarray-filtered analysis of age-matched human
liver specimens that identified 1,640 genes differentially
expressed according to sex [7]. Twenty-six of these genes
were utilized to determine which genes were also differen-
tially expressed in human kidney tissues. Four additional
transporter genes, which were previously noted as being
differentially expressed in the liver, MXR, MRP5, MRP1,
and ABCB1, were also examined [22]. As part of mRNA
expression analyses, an appropriate choice of housekeeping
gene(s) is critical. To confirm the utilization of a single
housekeeping gene, GAPDH, we averaged the GAPDH
cycle threshold (Ct) value of the 95 human kidney samples
as well as compared the average GAPDH Ct values based
on sex, age, and ethnicity. The average the GAPDH Ct
value (mean ± SEM) of the 95 human kidney samples was
30.47 ± 0.36. As shown in Figure 1, there was no significant
difference in average GAPDH Ct values (mean ± SEM)
based on sex (female: 29.94 ± 0.53 and male: 30.77 ± 0.48;
Figure 1A), age (age < 50 years: 31.00 ± 0.71 and
age ≥ 50 years: 30.32 ± 0.42; Figure 1B), and ethnicity
(African American: 29.91 ± 0.65 and European American:
30.65 ± 0.45; Figure 1C). Further analysis showed no
significant difference of GAPDH Ct values based on sex-age
(Figure 1D, Table 3) and sex-ethnicity (Figure 1E, Table 3)
interactions. Based on these findings, the use of a single
reference gene, GAPDH, is acceptable and the observed
change in regulation is reflective of the target gene not the
reference gene.
Of the 30 genes studied using GAPDH as the reference
gene, three genes, SLCO1B1, SLC30A1, and ACCN4,
whose mRNA expressions were detected in the liver, were
not detected in the kidney. Studies were conducted on
Table 2 List of primers utilized in this study































Joseph et al. Biology of Sex Differences  (2015) 6:4 Page 4 of 15sex, ethnic, and age differences among the remaining
27 genes.
Sex differences in the expression of transporters in
human renal samples
Filtering for differential expression by sex (fold change
ratio >1.5), twenty-one transporter genes (ABCA5,
ABCB6, MRP1, MRP5, MXR, OST-beta, KCNK5,
ATP2B2, TRPC4AP, SLC10A1, SLC6A16, SLC22A12,
SLC22A9, SLC31A1, SLC31A2, SLC35F5, SLC43A1,
SLC4A1AP, SLC5A10, SLC5A6, and SLC16A11) exhibited
higher expression in males compared to females (Figure 2).
Two transporter genes (ATP7B and SLC9A1) exhibited
higher expression in females compared to males, and the
remaining four genes (ABCB1, KCNJ8, SLC22A2, and
SLC25A13) were similarly expressed in males and females(Figure 2). However, when statistical analyses were per-
formed using multiple Student t-test (Sidak-Bonferroni
correction method), expression levels between male and
female were not found to be significantly differentiated.
Age differences in the expression of transporters in
human renal samples
The expression of the 27 drug transporters were
further analyzed to identify genes that demonstrated
age differences in gene expression in normal kidney
tissue (fold change ratio >1.5). We divided the hu-
man kidney samples into two groups based on age:
patients below 50 years old (<50 years) and patients
50 years and older (≥50 years). Here, we observed 13
transporter genes (MRP5, OST-Beta, KCNK5, ATP7B,
TRPC4AP, SLC22A9, SLC31A1, SLC31A2, SLC35F5,
AD E
B C
Figure 1 Comparison of expression level for housekeeping gene, GAPDH, based on sex, age, and ethnicity. Box-whisker plot demonstrates
cycle threshold (Ct) values from lower to upper quartiles intersected by median for (A) sex, (B) age, (C) ethnicity, (D) sex-age interaction, and
(E) sex-ethnicity interaction. Statistical analysis for sex, age, and ethnicity was performed using non-parametric Mann–Whitney test. Statistical analysis
for sex-age and sex-ethnicity interaction was performed using non-parametric Kruskal-Wallis test (see Table 3).
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biting higher mRNA expression levels in age ≥ 50
years compared to age <50 years (Figure 3). Seven
transporter genes (MRP1, MRP5, SLC10A1, SLC6A16,
SLC22A2, SLC22A12, and SLC25A13) exhibiting
higher mRNA expression levels in age <50 years com-
pared to age ≥ 50 years (Figure 3). And the remaining
seven genes (ABCA5, ABCB1, ABCB6, ATP2B2,Table 3 Statistical evaluation of GAPDH levels based on sex-a
Sex-age
Krustal-Wallis p value
Female <50 yrs vs. female ≥50 yrs >0.9999
Male <50 yrs vs. male ≥50 yrs >0.9999
Female <50 yrs vs. male <50 yrs >0.9999
Female ≥50 yrs vs. male ≥50 yrs >0.9999
Statistical differences between GAPDH Ct for sex-age and sex-ethnicity interactions
suitability as housekeeping gene. AA, African American; EA, European American.KCNJ8, SLC5A10, and SLC9A1) were similarly ex-
pressed in both age groups (Figure 3). This finding
suggests age may also be a factor that contributes to
differences in adverse responses in human kidney.
Statistical analyses using multiple Student’s t-test
(Sidak-Bonferroni correction method) between age <50
years and age ≥ 50 years were not found to be significantly
differentiated.ge and sex-ethnicity interactions
Sex-ethnicity
Krustal-Wallis p value
AA female vs. AA male 0.9998
EA female vs. EA male 0.8630
AA female vs. EA female 0.9967
AA male vs EA male 0.6098
were assessed by non-parametric paired Krustal-Wallis test. p > 0.05 indicates
Figure 2 Relative mRNA expression levels of drug transporters exhibiting sex differences in human kidney tissue. The 30 transporter
mRNA expressions for human kidney tissue were graphed to illustrated sex (male and female) differences. The bars represent the mean relative
mRNA expression; the error bars indicate the standard error mean from n > 3 samples. Statistical analysis was performed using multiple Student’s
t-test (Sidak-Bonferroni correction method (alpha = 5%)).
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in human renal samples
Interestingly, when the two sexes were further analyzed
and sub-grouped by age (females <50 years, males <50
years, females ≥50 years and males ≥50 years), we observed
sex- and age-related differentiation in gene expression of
drug transporters (Figure 4).
Evaluation of the expression levels of the 27 drug
transporter genes in females <50 years and males <50
years identified 14 transporter genes (ABCB6, MRP5,
MXR, KCNJ8, ATP7B, SLC6A16, SLC22A2, SLC22A12,
SLC25A13, SLC31A1, SLC35F5, SLC4A1AP, SLC5A10,
and SLC9A1) that were expressed higher in females <50
years compared to males <50 years. Using two-way
ANOVA with Bonferroni correction, the difference in ex-
pression was significant for one of the transporter genes,
SLC22A12 (p < 0.05). On the other hand, nine trans-
porter genes (ABCA5, SLC5A6, SLC10A1, SLC22A9,
SLC43A1, ATP2B2, KCNK5, OST-beta, and TRPC4AP)
were expressed higher in males <50 years compared to
females <50 years. And four transporter genes (ABCB1,
MRP1, SLC16A11, and SLC31A2) were similarly expressed
in males <50 years and females <50 years (Figure 4A).Comparing the expression levels of the 27 drug trans-
porter genes in females ≥50 years and males ≥50 years, we
observed 24 transporter genes (ABCA5, ABCB6, MRP1,
MRP5, MXR, OST-Beta, KCNK5, KCNJ8, ATP2B2,
TRPC4AP, SLC10A1, SLC6A16, SLC22A12, SLC22A9,
SLC25A13, SLC31A1, SLC31A2, SLC35F5, SLC43A1,
SLC4A1AP, SLC5A10, SLC5A6, SLC16A11, and SLC9A1)
that were expressed higher in males ≥50 years com-
pared to females ≥50 years (Figure 4B). The difference in
expression between females ≥50 years and males ≥50 years
was not significant using two-way ANOVA (Bonferroni
correction) analysis. And the remaining three transporter
genes (SLC22A2, ATP7B, and ABCB1) were similarly
expressed in females ≥50 years and males ≥50 years
(Figure 4B).
When the expression levels of the 27 drug transporter
genes were further investigated in females <50 years and
females ≥50 years, we observed 20 transporter genes
(ABCA5, ABCB1, ABCB6, MRP5, MXR, KCNJ8, ATP7B,
SLC6A16, SLC22A2, SLC22A12, SLC25A13, SLC31A1,
SLC31A2, SLC35F5, SLC43A1, SLC4A1AP, SLC5A10,
SLC5A6, SLC16A11, and SLC9A1) that were expressed
higher in females <50 years compared to females ≥50 years
Figure 3 Relative mRNA expression levels of drug transporters exhibiting age differences in human kidney tissue. The 30 transporter
mRNA expressions for human kidney tissue were graphed to illustrated age (age group: below 50 years old (<50 years) and age group: 50 years
and older (≥50 years)) differences. The bars represent the mean relative mRNA expression; the error bars indicate the standard error mean from
n > 3 samples. Statistical analysis was performed using multiple Student’s t-test (Sidak-Bonferroni correction method (alpha = 5%)).
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correction, females <50 years exhibited significantly higher
mRNA expression levels of four of these drug transport
genes; SLC22A2 (p < 0.01), SLC22A12 (p < 0.005), SLC6A16
(p < 0.05), and ABCB6 (p < 0.05) compared to females ≥50
years (Figure 4C). Five transporter genes (KCNK5,
OST-beta, ATP2B2, SLC10A1, and TRPC4AP) were
expressed higher in females ≥50 years compared to
females <50 years (Figure 4C). And two transporter
genes (SLC22A9 and MRP1) were similarly expressed in
females ≥50 years and females <50 years (Figure 4C).
Comparing the expression levels of the 27 drug trans-
porter genes in males <50 years and males ≥50 years, we
observed 23 transporter genes (ABCB6, MRP1, MRP5,
MXR, OST-Beta, KCNK5, KCNJ8, ATP7B, ATP2B2,
TRPC4AP, SLC10A1, SLC22A12, SLC22A9, SLC25A13,
SLC31A1, SLC31A2, SLC35F5, SLC43A1, SLC4A1AP,
SLC5A10, SLC5A6, SLC16A11, and SLC9A1) that were
expressed higher in males ≥50 years compared to males
<50 years (Figure 4D). And the remaining four transporter
genes (ABCA5, ABCB1, SLC6A16, and SLC22A2) weresimilarly expressed in males <50 years and males ≥50
years (Figure 4D). None of the genes were significantly
differentiated in expression between males ≥50 years and
males ≥50 years.
These findings suggest that the differences in drug
transporter mRNA expression levels may be influenced
by more than one factor. Here, we show the age of the
different sexes (male and female) can influence the
mRNA expression levels of several drug transporters.
Ethnic differences in the expression of transporters in
human renal samples
Differential expression by ethnic groups, European
American and African American, was also evaluated.
Twenty-two transporter genes (ABCA5, MRP1, MRP5,
MXR, OST-Beta, KCNK5, ATP7B, TRPC4AP, SLC10A1,
SLC6A16, SLC22A2, SLC22A12, SLC22A9, SLC25A13,
SLC31A1, SLC31A2, SLC35F5, SLC43A1, SLC4A1AP,
SLC5A10, SLC5A6, and SLC16A11) exhibited higher
expression in European Americans compared to African
Americans (Figure 5). In contrast, two transporter genes
Figure 4 Relative mRNA expression profiles exhibiting sex and age differences of drug transporters. The 30 transporter mRNA
expressions for human kidney tissue were graphed to illustrated sex and age differences: (A) males <50 years, (B) males ≥50 years, (C) females
<50 years, and (D) females ≥50 years. The bars represent the mean relative mRNA expression; the error bars indicate the standard error mean
from n > 3 samples. Statistical analysis was performed using two-way ANOVA (Bonferroni correction); *p < 0.05, **p < 0.05, and #p < 0.01.
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African Americans compared to European Americans
(Figure 5). And three transporter genes (ABCB1, ABCB6,
and KCNJ8) were similarly expressed in European
Americans and African Americans (Figure 5). This finding
suggests ethnicity may also be a factor that contributes to
differences in adverse responses in human kidney. Using
multiple Student’s t-test (Sidak-Bonferroni correction
method), statistical analyses were performed between the
expression levels of European American and African
Americans were found not to be significantly differentiated.Sex and ethnic differences in the expression of
transporters in human renal samples
Further analysis was performed to evaluate the gene
expression differences of the two sexes sub-grouped
by ethnicity (African American Males vs. European
American Males or African American Females vs. European
American Females).
When the expression levels of the 27 drug transporter
genes were further investigated in European American
males and African American males, 19 transporter genes
(ABCB6, MRP1, MXR, OST-Beta, KCNK5, KCNJ8, ATP2B2,
Figure 5 Relative mRNA expression levels of drug transporters exhibiting ethnicity differences in human kidney tissue. The 30
transporter mRNA expressions for human kidney tissue were graphed to illustrated ethnic (European American and African American) differences.
The bars represent the mean relative mRNA expression; the error bars indicate the standard error mean from n > 3 samples. Statistical analysis
was performed using multiple Student’s t-test (Sidak-Bonferroni correction method (alpha = 5%)).
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SLC31A1, SLC31A2, SLC43A1, SLC4A1AP, SLC5A10,
SLC5A6, and SLC16A11) exhibited higher expression
in European American males compared to African
American males (Figure 6A). On the other hand, four
transporter genes (ATP7B, SLC22A2, SLC35F5, and
SLC9A1) exhibited higher expression in African American
males compared to European American males (Figure 6A).
And four transporter genes (ABCA5, ABCB1, MRP5,
and SLC25A13) were similarly expressed in European
American and African American males (Figure 6A).
None of the genes found to be differentiated were
significantly expressed in European American males
and African American males.
Comparing the expression levels of the 27 drug
transporter genes in European American females and
African American females, ten transporter genes (MXR,
ATP2B2, TRPC4AP, SLC10A1, SLC6A16, SLC22A9,
SLC31A1, SLC5A10, ABCA5, and SLC16A11) exhibited
higher expression in European American females com-
pared to African American females. Nine transporter
genes (ABCB6, SLC31A2, MRP1, ATP7B, SLC22A2,OST-beta, KCNJ8, SLC35F5, and SLC9A1) the differences
in expression level were significant (Figure 6B). Our find-
ing showed that for two of these genes, ATP7B (p < 0.0.5)
and KCNJ8 (p < 0.05), which exhibited higher expression
in African American females compared to European
American females were found to be significant differences
in mRNA expression in the human kidney based on
two-way ANOVA with Bonferroni correction. The
remaining eight genes (KCNK5, ABCB1, MRP5,
SLC22A12, SLC43A1, SLC25A13, SLC4A1AP, and SLC5A6)
were similarly expressed in European American and
African American females (Figure 6B).
When the two ethnic groups, European American and
African American, were sub-grouped by sex, and gene
expression differences were evaluated between European
American females and European American males, 18
transporter genes (ABCA5, ABCB6, MRP1, MRP5,
OST-Beta, KCNK5, KCNJ8, TRPC4AP, SLC6A16,
SLC22A12, SLC31A1, SLC31A2, SLC35F5, SLC43A1,
SLC4A1AP, SLC5A10, SLC5A6, and SLC16A11) were
found to be higher expressed in European American males
compared to European American females (Figure 6C).
Figure 6 Relative mRNA expression profiles exhibiting sex and ethnic differences of drug transporters. The 30 transporter mRNA expressions
for human kidney tissue were graphed to illustrated sex and ethnic differences: (A) European American males, (B) European American females,
(C) African American males, and (D) African American females. The bars represent the mean relative mRNA expression; the error bars indicate the
standard error mean from n > 3 samples. Statistical analysis was performed using two-way ANOVA (Bonferroni correction); *p < 0.05.
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our finding demonstrated that one gene, SLC31A2
(p < 0.05), exhibited significant differences in mRNA
expression (Figure 6C). The remaining nine genes (ABCB1,
ATP2B2, ATP7B, MXR, SLC10A1, SLC22A9, SLC22A2,
SLC25A13, and SLC9A1) were similarly expressed in
European American females and males (Figure 6C).The expression levels of the 27 drug transporter genes
were further evaluated in African American males and
African American females. Fourteen transporter genes
(ABCA5, MRP5, MXR, ATP2B2, SLC6A16, SLC22A2,
SLC22A12, SLC22A9, SLC31A1, SLC31A2, SLC35F5,
SLC43A1, SLC5A10, and SLC16A11) exhibited higher
expression in African American males compared to African
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genes (ATP7B, KCNJ8, and SLC9A1) exhibited higher
expression in African American females compared to
African American males (Figure 6D). And the remaining
ten genes (ABCB1, ABCB6, KCNK5, MRP1, OST-beta,
SLC10A1, SLC25A13, SLC4A1AP, SLC5A6, and TRPC4AP)
were similarly expressed in African American males
and females (Figure 6D). None of the genes were
found to be significantly differentiated in expression
in African American males and African American
females.
The findings of the study strengthens our suggestion
that the differences in drug transporter mRNA expression
levels may also be influenced by more than one factor and
all three factors: sex, age, and ethnicity, impact the mRNA
expression levels of drug transporters in the kidney.
Discussion
In the kidney, tissue expression levels of drug transporters
can mediate the selective filtering, retention, and excretion
of renal drug and their metabolites [1-4]. However, there
are little data available about the expression levels of drug
transporters in normal human kidney, and most of the
existing data has been obtained from rat, mice, or cell
culture models. For this reason, the data previously
presented are sometimes conflicting. Studies have
shown that the expression of drug transporters in human
kidney cell lines and rat tissue do not always correlate with
the expression in human tissue from kidney [4]. These
studies have shown in human kidney tissue, for example,
that the transporter SLC22A1 (OCT1) is more commonly
expressed while in rat kidney tissue SLC22A2 (OCT2) and
SLC22A3 (OCT3) are most commonly expressed [4].
Differences in mRNA expression of drug transporters
have also been demonstrated between kidney cell lines
and human kidney tissue [4]. For example, SLC22A2
(OCT2) mRNA expression was detected in human kidney
tissue but not in the human kidney cell line Caki-1;
instead these cells expressed SLC22A3 (OCT3) [4].
Therefore, the use of kidney cell lines and rat tissue
as a model for understanding drug transporters in human
kidney should be approached with caution. For this
reason, we focused on the use of human kidney tissue to
assess the mRNA expression of drug transporters in deter-
mining sex, ethnic, and age differences in human kidney
tissues. Tissue derived from human kidney serves as a
more appropriate model for assessing the expression of
drug transporters in the human kidney.
In this study, we utilized mRNA expression profiles to
investigate the expression pattern of the 30 transporter
genes. Our results and conclusions are based on mRNA
expression data, which may not always correlate with the
expression of protein. Therefore, the mRNA expression
data shown for each gene must be considered as a startingpoint for assessing sex, ethnic, and age differences in
human kidney tissues. The assessment of differential gene
expression of drug transporters as a function of sex, age,
as well as ethnicity was the focus of this study.
One of the most critical aspects of mRNA expression
analyses is finding an appropriate choice of housekeeping
gene. Several studies have shown that using a single house-
keeping gene as a reference for renal studies may reflect
regulation of the reference gene rather than the target gene
[23,24]. These studies have shown that reference genes
have the potential of being differentially regulated based on
cell or tissue type as well as under certain conditions such
as cell proliferation and cancer [23-34]. In recent years, an
increasing number of publications have indicated the
need of multiple/combination of housekeeping genes
be considered as reference for QRT-PCR. Several
studies have been conducted to identify acceptable
housekeeping genes for QRT-PCR analyses using human
renal samples. Dupasquier et al. [23] evaluated eight
potential housekeeping genes for their expression level
and stability to minimize inter-individual variations
between clear cell renal cell carcinoma (ccRCC) samples
and their corresponding healthy tissue. Of the eight
housekeeping genes studied, peptidylpropyl isomerase A
(PPIA also called cyclophilin A) and ribosomal protein
S13 (RPS13), especially in combination, were best suitable
to normalize gene expression in cancer and normal tissue
[23]. In another study, Schmid et al. [24] assessed three
commonly used housekeeping genes, GAPDH, 18SrRNA,
and cyclophilin A, in 165 human kidney biopsies,
which consisted of 22 controls (normal tissue) and 143
nephropathy tissues with a variety of histopathologic
diagnoses. The data from this study recommended the use
of 18SrRNA and cyclophilin A as housekeeping genes for
gene expression analysis of tubulointersitial compartments
and non-microdissected kidney biopsies [24]. Both studies
focus on differences in the expression of the housekeeping
gene under two different conditions, normal and cancer/
diseased tissue, and indicate that using two or more house-
keeping genes allows for the detection of any systematic
bias that may arise. Here, we are focused on only one con-
dition, normal tissue, and used GAPDH as the reference
gene. GAPDH remains the most widely used housekeeping
gene employed in QRT-PCR gene expression analyses and,
based on our study parameters, is an acceptable reference
control. Our findings indicate GAPDH as a reference gene
in our study does not significantly influence the observed
changes in drug transporter mRNA expression.
We determined that genes were differentially expressed
if their expression ratio was greater than 1.5. A difference
in expression was observed between the sex, age, and
ethnicity as shown in Figures 2, 3, and 5, respectively.
However, based on statistical analysis performed, multiple
Student’s t-test with Sidak-Bonferroni correction method
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while differentially expressed were not found to be signifi-
cant. This trend was also observed with age-only (age: <50
years and age: ≥50 years) and ethnic-only (European
American and African American) analyses. The lack of
statistical significance in the study may be due to genomic
variations displayed in human tissue samples, which
modulate their expression as well as the sample size. To
determine if the study was suitably statistically powered to
detect differences, we evaluated the power of the
completed study. Using the sample sizes and the
standard deviation observed, it was concluded that
sex-only, age-only, and the ethnicity-only analyses have an
average of 53%, 22%, and 28% chance (power), respectively,
to detect significant difference. Therefore, a larger sample
size may increase the significance of this study.
Our results showed that three transporters, ACCN4,
SLCO1B1, and SLC30A1, were not expressed in the human
kidney tissues. SLCO1B1, a liver-specific member of the
organic anion transporter (OAT) family, and ACCN4 have
been found mainly in the liver [11,35,36]. SLC30A1 has
been found to be expressed in both human embryonic
kidney 293 cells and normal human kidney tissue. These
findings need to be evaluated further.
The remaining 27 transporters previously found to be
expressed in the liver were found to be expressed in the
human kidney. Of these genes, 23 were found to exhibit
sex-bias in their mRNA expression levels, with 21 of the
transporter genes exhibiting male dominance in expres-
sion and two of the transporter genes exhibiting female
dominance in expression. Awareness of sex differences
in response to drug bioavailability, distribution, and
clearance is clinically important. Sex differences have
been shown to contribute to adverse drug responses,
which has drawn significant attention in recent years as
many studies have shown women having a greater risk of
suffering adverse drug responses than men [1,7,8,10,12,13].
For example, aspirin, an anti-inflammatory agent, is more
rapidly cleared from women and its metabolite, salicylate,
has an increased rate of absorption in women [11,36].
On the other hand, agents such as gemcitabine, a
chemotherapeutic drug, and heparin, an anticoagulant,
have a lower clearance rate in women [11,23]. Sex-specific
differences in expression levels of drug transporters have
been implicated in the induction of sex-specific toxicities
in the kidney contributing to sex-related renal disease and
injuries [37-40]. For example, male rats lack the sex-specific
protection against mercury-induced nephrotoxicity
observed in female rats [38]. One of the drug transporters
that exhibited male dominance bias in this study was
MRP, which was seven times (7×) more highly expressed
in males compared to females. MRP1, a member of ABC
superfamily, has been identified as a transporter for the
pharmaceutical agent, adefovir [35]. Initially, the use ofadefovir was proposed for the treatment of HIV. This was
not approved by the Food and Drug Administration due
to concerns about the severe and frequent cases of kidney
toxicity associated with high doses of the drug [41]. This
drug was repurposed and approved for the treatment of
chronic hepatitis B virus infections at lower doses [41].
The warning label for adefovir indicates the risk of adverse
drug reactions is higher in women. Our finding is support-
ive as we demonstrated that males have higher mRNA
expression levels of MRP1 compared to females. The sex-
biased expression pattern of drug transporters may provide
explanations for clinical observations of sex-dependent
pharmacokinetics. However, focused studies are needed to
determine whether sex differences affect drug transport,
adverse drug interactions, or drug-drug interactions.
Aging is another factor that contributes to differences
in pharmacokinetic and pharmacodynamic behaviors.
Aging is associated with a decline in the ability to
metabolize and transport some drugs but there are very
little data available on the clinical outcomes of dose
modification, particularly at ages greater than 50 years
(>50 years). For most pharmaceutical agents, dosage
adjustment in older people is restricted to pharmacokinetic
studies in small populations of healthy volunteers [5]. In
older people, age-related changes in the pharmacokinetics
and pharmacodynamics of drugs may increase the risks of
toxicity or limit efficacy [14-16,42]. In addition, elder
patients may demonstrate variable degrees of membrane
nephropathy and nephrosclerosis, which affect the kidney
function [43]. Recent studies have identified novel
mechanisms for age-related changes in hepatic pharmacol-
ogy and toxicology [5,9,44]. Zhang et al. [44] showed in
mice liver that aging has been associated with decreased
mRNA expression of solute carrier superfamily, specifically
the solute carrier organic anion (SLCO) subfamily and
solute carrier subfamily 22 (SLC22s). Furthermore, the
mRNA expressions of several efflux transporters, including
multidrug resistant proteins (MRP-2, MRP6, and MRP3),
have been shown to be significantly reduced in livers
of older mice [44]. In rat tissue, Kwekel et al. [17]
demonstrated that two drug transporters, SLCO1A1
and SLC22A7, exhibited different expression patterns
during the aging cycle. SLCO1A1 mRNA expression
at the early age of 2 weeks showed low expression
levels followed by a rapid increase in expression levels
from age 5 to 21 weeks, followed by diminishing expres-
sion levels into adulthood. On the other hand, SLC22A7
was expressed at low levels between ages 2 and 8 weeks
with a significant increase in expression levels in later
adulthood in rats [17]. However, what this means in terms
of how it translates to humans remains undetermined. In
this study, we identified drug transporter genes with
age-related changes in mRNA expression in human
kidney tissue. Here, we showed that 13 of the 27 drug
Joseph et al. Biology of Sex Differences  (2015) 6:4 Page 13 of 15transporter studied exhibited an age-bias with individuals
aged 50 or greater (≥50) years showing dominance and
seven of the 27 drug transporter studied exhibited an
age-bias with individuals aged less than 50 (<50) years
showing dominance in mRNA expression. Due to the fact
that the majority of age-related studies were performed in
rats, limited data in normal human tissue are available to
compare with our data. Other studies have also highlighted
sex and age-associated changes in drug pharmacokinetics
in persons of older ages [6,16,45]. Here, we demonstrated
that the expression level varies among the sub-groups of
sex and age: males <50 years, males ≥50 years, females <50
years, and females ≥50 years. We showed that women
of age less than 50 (<50) had significantly higher
levels of mRNA expression for the four drug transporters,
SLC22A12, SLC22A2, SCL6A16, and ABCB6. These age-
dependent changes in drug transporter expression in
women may be due to changes in the levels of hormones
such as estrogen [46,47] as well as medication use. Studies
have implicated higher use of medication in women [48]
and elderly [16]. Also, several medications have been
shown to potentially influence expression of drug
transporters, e.g., steroids may upregulated P-gp [49].
Ethnic inequality in treatment outcomes is a problem
that is receiving increased recognition in clinical oncology.
It is not completely clear whether differences noted
between European Americans and African Americans in
treatment outcomes are due to matters of patient access
to care, differences in medical care delivery, differences in
clinical response to the same therapies, genetic variability
or, most likely, a combination of these factors [50].
Man et al. [20] assessed the genetic variations of DMETs
across three major ethnic populations: Africans, Caucasians,
and East Asians. They demonstrated that genetic
differences occurred among the three major ethnic
groups, which accounted for observed differences in their
respective drug transporter function while among the East
Asian subgroups, Chinese, Korean, and Japanese, genetic
similarities were observed [20]. In this study, we
focused on differences in gene expression between
African American and European Americans for drug
transporters, which may aid in our understanding of
racial disparity demonstrated in treatment outcomes. In
this study, we observed 22 of the 27 transporter genes stud-
ied exhibiting higher expression in European American
compared to African Americans. And two of the 27 trans-
porter genes studied exhibiting higher expression in African
American compared to European Americans. One of
these genes, SLC22A2 (OAT2), which is expressed
three times (3×) higher in European Americans com-
pared to African Americans, has been identified as a
transporter for cisplatin. Cisplatin, a platinum-based
anticancer agent, has been shown to induce higher
rates of nephrotoxicity in African Americans [19].Our data showed lower expression levels of SLC22A2,
an uptake drug transporter, in African Americans. These
data imply that other drug transporters with the ability
to transport cisplatin or epigenetic factors may be contrib-
uting to cisplatin-induced nephrotoxicity observed in
African Americans. The differences in drug transporters
gene expression between different ethnicities as well the
influence of ethnicity on sex may contribute to clinical
treatment outcomes.Conclusions
The kidney is one of the main pharmacokinetic organs;
therefore, the ability to make regulatory decisions
regarding the impact of drugs and other chemicals on
the kidney is dependent upon understanding of kidney
biology and, more specifically, the expression profiles of
the molecular components that play a role in pharmaco-
kinetics, pharmacodynamics, and toxicokinetics in kidney
tissue. Most studies have utilized rat tissue as an in vivo
model. Our findings on the expression of drug trans-
porters in human kidney tissue and the identification of
factors that influence the drug transporter expression, sex,
age, and/or ethnicity, improve our understanding of
the impact of active drug transport processes on the
pharmacokinetics and distribution of drugs in human
kidney. The sex, age, and ethnic differences of drug
transporters in the normal human kidney may be due
to epigenetic modifications of these genes, a factor
that needed to be further considered. With larger
sample sizes, the differences in expression levels observed
may be found to be significant. Our data also suggest that
the three factors: sex, age, and race, may, at times,
simultaneously influence adverse drug responses in
the human kidney and drug-drug interactions.
Abbreviations
QRT-PCR: Quantitative real-time polymerase chain reaction; ABCs: ATP-
binding cassettes; SLCs: Solute carriers; DMETs: Drug metabolizing enzymes
and transporters; CHTN: Cooperative Human Tissue Networks;
cDNA: Complimentary deoxyribonucleic acid; RT-PCR: Reverse transcribed
polymerase chain reaction; FDA: Food and Drug Administration;
RIHSC: Research Involving Human Subject Committee; AA: African American;
EA: European American; ccRCC: Clear cell renal cell carcinoma;
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; RNA: Ribonucleic acid;
18S rRNA: 18S ribosomal ribonucleic acid; PPIA: Peptidylpropyl isomerase A
or cyclophilin A; RPS13: Ribosomal protein S13; OAT: Organic anion
transporter; MRP: Multidrug-resistant proteins; mRNA: Messenger ribonucleic
acid; KCN: Potassium family subfamily.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SJ, TJN, and BLC conceived and designed the experiments. SJ, BLC, GH, BW,
and BGK performed experiments involving isolation of biological materials
from tissue samples. SJ performed the QRT-PCR experiments and statistical
analysis. SJ, BLC, and GH wrote and reviewed the manuscript. All authors
read and approved the final manuscript.
Joseph et al. Biology of Sex Differences  (2015) 6:4 Page 14 of 15Acknowledgements
The initial study was funded by a grant from the FDA Office of Women
Health (OWH).Disclaimer
The views presented in this report do not necessarily reflect those of the US
Food and Drug Administration.
Author details
1Division of Biochemical Toxicology, National Center for Toxicological
Research, Food and Drug Administration, Building 50, Room 630, HFT 100,
3900 NCTR Road, Jefferson, AR 72079, USA. 2Drug Discovery and
Development, London, UK. 3Divison of Systems Biology, National Center for
Toxicological Research, Food and Drug Administration, Jefferson, AR
72079-9502, USA.
Received: 3 October 2014 Accepted: 10 January 2015
References
1. Kwekel JC, Desai VG, Moland CL, Vijay V, Fuscoe JC. Sex differences in kidney
gene expression during the life cycle of F344 rats. Biol Sex Differ. 2013;4:14.
2. Sabolic I, Asif AR, Budach WE, Wanke C, Bahn A, Burckhardt G. Gender
differences in kidney function. Pflugers Arch. 2007;455:397–429.
3. Trevisan A, Chiara F, Mongillo M, Quintieri L, Cristofori P. Sex-related
differences in renal toxicodynamics in rodents. Expert Opin Drug Metab
Toxicol. 2012;8:1173–88.
4. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J.
Expression of thirty-six drug transporter genes in human intestine, liver,
kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35:1333–40.
5. McLachlan AJ, Hilmer SN, Le Couteur DG. Variability in response to
medicines in older people: phenotypic and genotypic factors.
Clin Pharmacol Ther. 2009;85:431–3.
6. Wilkinson GR. Drug metabolism and variability among patients in drug
response. N Engl J Med. 2005;352:2211–21.
7. Yang L, Hong H, Chang C-W, Guo L-W, Lyn-Cook B, Shi L, et al. Sex
differences in the expression of drug-metabolizing and transporter genes
in human liver. J Metab Toxicol. 2012;3:1–9.
8. Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, et al. Gene expression
variability in human hepatic drug metabolizing enzymes and transporters.
PLoS One. 2013;8:e60368.
9. Kwekel JC, Desai VG, Moland CL, Branham WS, Fuscoe JC. Age and sex
dependent changes in liver gene expression during the life cycle of the rat.
BMC Genomics. 2010;11:675.
10. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity.
Trends Pharmacol Sci. 2010;31:108–14.
11. Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition.
J Biochem Biotechnol. 2011;2011:14.
12. Tanaka E. Gender-related differences in pharmacokinetics and their clinical
significance. J Clin Pharm Ther. 1999;24:339–46.
13. Committee on Understanding the Biology of Sex and Gender Differences.
Exploring the biological contributions to human health: does sex matter?
J Womens Health Gend Based Med. 2001;10:433–9.
14. Bowman L, Carlstedt BC, Hancock EF, Black CD. Adverse drug reaction (ADR)
occurrence and evaluation in elderly inpatients. Pharmacoepidemiol Drug
Saf. 1996;5:9–18.
15. Hall MR. Adverse drug reaction in the elderly. Gerontol Clin (Basel).
1974;16:144–50.
16. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in
elderly patients. Br J Clin Pharmacol. 2004;57:121–6.
17. Kwekel JC, Desai VG, Moland CL, Vijay V, Fuscoe JC. Life cycle analysis of
kidney gene expression in male F344 rats. PLoS One. 2013;8:e75305.
18. Williams LK, Padhukasahasram B, Ahmedani BK, Peterson EL, Wells KE,
González Burchard E, et al. Differing effects of metformin on glycemic
control by race-ethnicity. J Clin Endocrinol Metab. 2014;99(9):3160–8.
19. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent
medications on cisplatin-induced nephrotoxicity in patients with head and
neck cancer. Anticancer Drugs. 2006;17:207–15.
20. Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic
variation in metabolizing enzyme and transporter genes: comprehensiveassessment in 3 major East Asian subpopulations with comparison to
Caucasians and Africans. J Clin Pharmacol. 2010;50:929–40.
21. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. Variability in mRNA
expression of ABC- and SLC-transporters in human intestinal cells: comparison
between human segments and Caco-2 cells. Eur J Pharm Sci. 2006;28:291–9.
22. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein:
from genomics to mechanism. Oncogene. 2003;22:7468–85.
23. Dupasquier S, Delmarcelle AS, Marbaix E, Cosyns JP, Courtoy PJ, Pierreux CE.
Validation of housekeeping gene and impact on normalized gene
expression in clear cell renal cell carcinoma: critical reassessment of
YBX3/ZONAB/CSDA expression. BMC Mol Biol. 2014;15:9.
24. Schmid H, Cohen CD, Henger A, Irrgang S, Schlondorff D, Kretzler M.
Validation of endogenous controls for gene expression analysis in
microdissected human renal biopsies. Kidney Int. 2003;64:356–60.
25. Sirover MA. Role of the glycolytic protein, glyceraldehyde-3-phosphate
dehydrogenase, in normal cell function and in cell pathology. J Cell
Biochem. 1997;66:133–40.
26. Hendriks-Balk MC, Michel MC, Alewijnse AE. Pitfalls in the normalization of
real-time polymerase chain reaction data. Basic Res Cardiol. 2007;102:195–7.
27. Guenin S, Mauriat M, Pelloux J, Van Wuytswinkel O, Bellini C, Gutierrez L.
Normalization of qRT-PCR data: the necessity of adopting a systematic,
experimental conditions-specific, validation of references. J Exp Bot.
2009;60:487–93.
28. Vila MR, Nicolas A, Morote J, de I, Meseguer A. Increased glyceraldehyde-3-
phosphate dehydrogenase expression in renal cell carcinoma identified by
RNA-based, arbitrarily primed polymerase chain reaction. Cancer. 2000;89:152–64.
29. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, et al.
Housekeeping genes as internal standards: use and limits. J Biotechnol.
1999;75:291–5.
30. Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, et al.
‘Desperate house genes’: the dramatic example of hypoxia. Br J Cancer.
2010;102:1037–43.
31. Mansur NR, Meyer-Siegler K, Wurzer JC, Sirover MA. Cell cycle regulation of
the glyceraldehyde-3-phosphate dehydrogenase/uracil DNA glycosylase
gene in normal human cells. Nucleic Acids Res. 1993;21:993–8.
32. Selvey S, Thompson EW, Matthaei K, Lea RA, Irving MG, Griffiths LR.
Beta-actin–an unsuitable internal control for RT-PCR. Mol Cell Probes.
2001;15:307–11.
33. Rocha-Martins M, Njaine B, Silveira MS. Avoiding pitfalls of internal controls:
validation of reference genes for analysis by qRT-PCR and Western blot
throughout rat retinal development. PLoS One. 2012;7:e43028.
34. Ruan W, Lai M. Actin, a reliable marker of internal control? Clin Chim Acta.
2007;385:1–5.
35. Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on
metabolizing enzyme-transporter interplay and its role in drug interactions:
challenges in predicting drug interactions. Mol Pharm. 2009;6:1766–74.
36. Muller F, Fromm MF. Transporter-mediated drug-drug interactions.
Pharmacogenomics. 2011;12:1017–37.
37. Al-Rejaie SS, Abuohashish HM, Alkhamees OA, Aleisa AM, Alroujayee AS.
Gender difference following high cholesterol diet induced renal injury and
the protective role of rutin and ascorbic acid combination in Wistar albino
rats. Lipids Health Dis. 2012;11:41.
38. Hazelhoff MH, Bulacio RP, Torres AM. Gender related differences in kidney
injury induced by mercury. Int J Mol Sci. 2012;13:10523–36.
39. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal
disease. Curr Opin Nephrol Hypertens. 2001;10:219–25.
40. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend
Med. 2008;5(Suppl A):S3–S10.
41. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected
patients. Kidney Int. 2005;67:393–403.
42. Tangiisuran B, Wright J, Van der Cammen T, Rajkumar C. Adverse drug
reactions in elderly: challenges in identification and improving preventative
strategies. Age Ageing. 2009;38:358–9.
43. Carmo PA, Kirsztajn GM, Carmo WB, Franco MF, Bastos MG.
Histopathological findings in elderly patients. J Bras Nefrol. 2010;32:286–91.
44. Zhang YK, Saupe KW, Klaassen CD. Energy restriction does not compensate
for the reduced expression of hepatic drug-processing genes in mice with
aging. Drug Metab Dispos. 2010;38:1122–31.
45. Sweeney DE, Vallon V, Rieg T, Wu W, Gallegos TF, Nigam SK. Functional
maturation of drug transporters in the developing, neonatal, and postnatal
kidney. Mol Pharmacol. 2011;80:147–54.
Joseph et al. Biology of Sex Differences  (2015) 6:4 Page 15 of 1546. Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential
cellular, biochemical, and molecular mechanisms. Am J Physiol Renal
Physiol. 2001;280:F365–388.
47. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT
prolongation in women during the menstrual cycle. JAMA. 2001;285:1322–6.
48. Miller MA. Gender-based differences in the toxicity of pharmaceuticals—the
Food and Drug Administration’s perspective. Int J Toxicol. 2001;20:149–52.
49. Chan GN, Saldivia V, Yang Y, Pang H, de Lannoy I, Bendayan R. In vivo
induction of P-glycoprotein expression at the mouse blood–brain barrier:
an intracerebral microdialysis study. J Neurochem. 2013;127:342–52.
50. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in
response to drugs: focus on clinical pharmacology studies. Clin Pharmacol
Ther. 2008;84:417–23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
